托马斯·兰佐(Thomas Rantzau)在22年后离开诺沃·诺迪斯克的董事会;塔尼亚·维卢姆森接任。 Thomas Rantzau departs Novo Nordisk’s board after 22 years; Tanja Villumsen succeeds him.

Thomas Rantzau于2026年1月31日离开Novo Nordisk的董事会, Thomas Rantzau is leaving Novo Nordisk’s Board of Directors on January 31, 2026, after 22 years with the company and four years as employee representative. 他的离任标志着他的董事会任期结束,由他的候补人Tanja Villumsen立即接管这一角色。 His departure marks the end of his board tenure, with Tanja Villumsen, his alternate, taking over the role effective immediately. 这一过渡是日常公司治理的一部分,没有提供关于Rantzau未来计划或Villumsen背景的进一步细节。 The transition was part of routine corporate governance, with no further details provided about Rantzau’s future plans or Villumsen’s background. 1923年创立的丹麦一家医疗保健公司Novo Nordisk继续通过创新和全球服务倡议,重点治疗糖尿病等慢性病。 Novo Nordisk, a Danish healthcare company founded in 1923, continues its focus on treating chronic diseases like diabetes through innovation and global access initiatives.